MobbleOpen in Mobble ⇢
Health · Drug development · published 2026-09-01 · via BiopharmaWatch

Key FDA PDUFA Dates Loom in September 2026 for Several Therapies

Image via BiopharmaWatch
Image via BiopharmaWatch

The FDA has several upcoming drug approval decisions in September 2026, including Zilurgisertib for fibrodysplasia ossificans progressiva on September 26 and Apitegromab for spinal muscular atrophy on September 30. Additionally, Ameluz photodynamic therapy for superficial basal cell carcinoma is slated for September 28. Other candidates are also pending review this month.

Read the full article at BiopharmaWatch →
Related stories
FDA Approves Takeda's Orexin-Targeting Narcolepsy Drug · Drug development
Regulators Revisit Approval Pathway for Plant-Based Therapies · Drug development
This summary is AI-generated and original to Mobble; the linked article is the authoritative source. Original headline: “FDA Calendar September 2026: Upcoming Drug Approval Decisions.” Browse more stories.